POLL — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Guttiferone K (SCHEMBL717385)	0.72	7/20
SCHEMBL294381	0.47	7/20
Garcinol (SCHEMBL294532)	0.47	7/20
Guttiferone F (SCHEMBL4607088)	0.47	7/20
Xanthochymol (SCHEMBL294395)	0.47	7/20
SCHEMBL4229280	0.42	7/20
SCHEMBL4226833	0.40	7/20
SCHEMBL4213930	0.40	6/20
SCHEMBL4221397	0.40	6/20
SCHEMBL4219802	0.40	6/20
SCHEMBL878788	0.38	5/20
SCHEMBL8172837	0.51	4/20
Clusianone (SCHEMBL8206884)	0.49	3/20
SCHEMBL8215247	0.46	3/20
SCHEMBL878771	0.45	3/20
SCHEMBL5598159	0.45	3/20
SCHEMBL6366589	0.71	2/20
SCHEMBL7911252	0.67	2/20
SCHEMBL8176587	0.64	2/20
SCHEMBL3054875	0.63	2/20

Clinical trials — most relevant to POLL by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection	PHASE3	UNKNOWN
Intracameral Antibiotic Safety Study	PHASE3	SUSPENDED
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	COMPLETED
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	UNKNOWN
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)	PHASE2	RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Combination Therapy Using Cellcept and Rebif in RRMS	EARLY_PHASE1	COMPLETED
Implementation of Molecular Diagnostic Pathways	nan	UNKNOWN
A Diabetes Improvement in Medical Therapy Versus SADJB Study	nan	UNKNOWN
Chromosomal Translocations in Chandigarh Police	nan	COMPLETED
ACE Gene Polymorphism and ARDS Outcome	nan	COMPLETED
The Impact of Myomectomy on IVF Outcomes	nan	NOT_YET_RECRUITING
Clinical Efectiveness of a Multiplex PCR-Based Rapid Diagnostic Method in Bloodstream Infections	nan	RECRUITING
The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia	nan	COMPLETED
Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia	nan	COMPLETED
Characterization of Sperm Population Following Different Selection Procedures	nan	UNKNOWN
Pilot Study on Molecular Quantitation and Sequencing of Endometrial Cytokines Gene Expression and Their Effect on the Outcome of In-vitro Fertilization (IVF) Cycle	nan	UNKNOWN
Effect of PCR-CRISPR/Cas12a on the Early Anti-infective Schemes in Patients With Open Air Pneumonia	nan	UNKNOWN
Large-scale COVID-19 Population Screening	nan	UNKNOWN
Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta	nan	UNKNOWN
Epigenetic Impact of a Psychotherapeutic Program in Adolescents With Severe Adverse Experiences	nan	COMPLETED
The Prevelence of HBB c.93-21 G-A in β Thalassemia Patients	nan	UNKNOWN
Efficacy of Access Flap Surgery on Subgingival Peridontopatgogens in Individuals With Periodontitis	nan	COMPLETED
VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol	nan	NOT_YET_RECRUITING
Colonization and Persistence Capacity of a Multi-strain Probiotics in Pediatric Food Allergy to Milk or Egg.	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a POLL binder may also engage these)

Protein	Name	Similarity
Q4R380	—	1.000	Q4R380 →
Q9QXE2	—	1.000	Q9QXE2 →
Q5RKI3	—	0.999	Q5RKI3 →
Q91ZJ0	—	0.990	Q91ZJ0 →
Q4KM32	—	0.984	Q4KM32 →
Q8VDP3	—	0.983	Q8VDP3 →
E9QAM5	—	0.983	E9QAM5 →
Q3SYT1	—	0.983	Q3SYT1 →
A0A8C2MDK8	—	0.983	A0A8C2MDK8 →
D3ZEY4	—	0.982	D3ZEY4 →
MUS81	Structure-specific endonuclease subunit MUS81	0.982	landscape →
Q8C9A2	—	0.982	Q8C9A2 →
Q640B4	—	0.982	Q640B4 →
ENGASE	Cytosolic endo-beta-N-acetylglucosaminidase	0.982	landscape →
Q9UIF7	—	0.982	Q9UIF7 →
O75064	—	0.982	O75064 →
Q9ESK3	—	0.981	Q9ESK3 →
Q6P5E8	—	0.981	Q6P5E8 →
A7YY46	—	0.981	A7YY46 →
Q8N490	—	0.981	Q8N490 →
D3ZBP4	—	0.981	D3ZBP4 →
Q0IHN5	—	0.981	Q0IHN5 →
Q8BHW9	—	0.981	Q8BHW9 →
Q9JJL8	—	0.980	Q9JJL8 →
A6H751	—	0.980	A6H751 →
Q9WTK5	—	0.980	Q9WTK5 →
JAK3	Tyrosine-protein kinase JAK3	0.980	landscape →
Q2M296	—	0.979	Q2M296 →
Q5JTZ9	—	0.979	Q5JTZ9 →
Q9BZG8	—	0.979	Q9BZG8 →